您的位置：首页 > 产品中心 > 1116235-97-2， GSK1838705A
GSK1838705A
产品别名
1116235-97-2
GSK1838705A
2-[[2-[[1-[(Dimethylamino)ethanoyl]-5-(methyloxy)-2,3-dihydro-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide
2-[[2-[[1-[2-(Dimethylamino)acetyl]-2,3-dihydro-5-methoxy-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methyl-benzamide
基本信息
| Empirical Formula【经验(实验)分子式】 | C27H29FN8O3 |
| Molecular weight | 532.57 |
| NACRES | NA.77 |
| Application【应用】 | GSK1838705A has been used as an insulin receptor inhibitor in Roswell Park memorial institute medium (RPMI) 1640 medium for inhibitor experiments, to prove that the induction of interleukin-1 β (IL-1β) is dependent on insulin receptor signaling. |
| Biochem/physiol Actions【生化/生理作用】 | GSK1838705A can be used to treat prostate cancer (PC). It is capable of decreasing the viability of docetaxel-sensitive and docetaxel-resistant prostate cancer cells. GSK1838705A can stimulate apoptosis of PC-3R cells. It is an alternative therapeutic option for crizotinib-resistant anaplastic large cell lymphoma (ALCL). GSK1838705A is a cell penetrant anti-tumor agent that potently inhibits the insulin-like growth factor-I receptors (IGF-IR), insulin receptors (IR) and anaplastic lymphoma kinase (ALK). GSK1838705A potently inhibits cell proliferation of multiple solid and hematologic cancers and retards the growth of human tumor xenografts. GSK1838705A does not significantly affect other kinases. GSK1838705A has minimal effects on glucose homeostasis in mice. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| color【颜色】 | white to light brown |
| solubility【溶解性】 | DMSO: 20 mg/mL, clear |
| storage temp.【储存温度】 | −20℃ |
安全信息
| Storage Class Code【储存分类代码】 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
